Methods used to assess pulmonary deposition and absorption of drugs.

The assessment of pulmonary drug absorption and deposition is becoming increasingly important in drug development. Absorption information can be used to maximize pulmonary selectivity, to screen drug candidates and to help evaluate the bioequivalence of generic inhalation products. Several methods are available to investigate pulmonary drug absorption and deposition, ranging from in vitro experiments to in vivo pharmacokinetic and pharmacodynamic analyses. In combination, these methods can indicate the fate of an inhaled drug.

[1]  J. Fleming,et al.  Three-dimensional description of pulmonary deposition of inhaled aerosol using data from multimodality imaging. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  H. Kostenbauder,et al.  Isolated perfused rabbit lung as a model for intravascular and intrabronchial administration of bronchodilator drugs I:Isoproterenol. , 1982, Journal of pharmaceutical sciences.

[3]  D. Argenti,et al.  A Pharmacokinetic Study to Evaluate the Absolute Bioavailability of Triamcinolone Acetonide following Inhalation Administration , 1999, Journal of clinical pharmacology.

[4]  J. Baskerville,et al.  A study of the mechanism of the antiasthmatic action of inhaled budesonide. , 1990, The Journal of allergy and clinical immunology.

[5]  V. H. Lee,et al.  Respiratory epithelial cell culture models for evaluation of ion and drug transport , 1996 .

[6]  J. Brain,et al.  Mechanisms, measurement, and significance of lung macrophage function. , 1992, Environmental health perspectives.

[7]  B. Lipworth,et al.  Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices. , 1997, Pulmonary pharmacology & therapeutics.

[8]  W. Bennett,et al.  Dual pathway clearance of 99mTc-DTPA from the bronchial mucosa. , 1989, The American review of respiratory disease.

[9]  Z. Lee,et al.  Pulmonary distribution and kinetics of inhaled [11C]triamcinolone acetonide. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  A. Hickey,et al.  Drug properties affecting aerosol behavior. , 2000, Respiratory care.

[11]  H. Möllmann,et al.  Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol. , 1992, International journal of clinical pharmacology, therapy, and toxicology.

[12]  I. Gonda.  Drugs administered directly into the respiratory tract: modeling of the duration of effective drug levels. , 1988, Journal of pharmaceutical sciences.

[13]  B. Lipworth,et al.  PHARMACOKINETICS AND DISPOSITION , 1997 .

[14]  J S Fleming,et al.  A new method of quantification of the pulmonary regional distribution of aerosols using combined CT and SPECT and its application to nedocromil sodium administered by metered dose inhaler. , 1994, The British journal of radiology.

[15]  G. Digenis,et al.  Gamma scintigraphy: an evolving technology in pharmaceutical formulation development-Part 1 , 1998 .

[16]  K. Rabe,et al.  Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. , 1997, The European respiratory journal.

[17]  Newman,et al.  Imaging techniques for assessing drug delivery in man. , 1999, Pharmaceutical science & technology today.

[18]  P R Byron,et al.  A novel dosing method for drug administration to the airways of the isolated perfused rat lung. , 1988, Journal of pharmaceutical sciences.

[19]  J. Widdicombe,et al.  Airway and alveolar permeability and surface liquid thickness: theory. , 1997, Journal of applied physiology.

[20]  Alexander A. Maximow,et al.  A Textbook of Histology , 1935, The Indian Medical Gazette.

[21]  M Lippmann,et al.  Interspecies comparisons of particle deposition and mucociliary clearance in tracheobronchial airways. , 1984, Journal of toxicology and environmental health.

[22]  S. Anderson,et al.  Regional deposition of saline aerosols of different tonicities in normal and asthmatic subjects. , 1994, The European respiratory journal.

[23]  H. Chrystyn.  Methods to determine lung distribution of inhaled drugs - could gamma scintigraphy be the gold standard? , 2000, British journal of clinical pharmacology.

[24]  P. Byron.  Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. , 1986, Journal of pharmaceutical sciences.

[25]  L. Schanker,et al.  Lung pH and pulmonary absorption of nonvolatile drugs in the rat. , 1977, Drug metabolism and disposition: the biological fate of chemicals.

[26]  M. Zureik,et al.  Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. , 1994, The European respiratory journal.

[27]  D. Rogers,et al.  Determining equivalence of inhaled medications. Consensus statement from a workshop of the British Association for Lung Research, held at Royal Brompton National Heart & Lung Institute, London 24 June 1994. , 1995, Respiratory medicine.

[28]  Jerome J. Schentag,et al.  Achieving an Optimal Outcome in the Treatment of Infections , 1999, Clinical pharmacokinetics.

[29]  A. Ryrfeldt,et al.  Uptake and biotransformation of ibuterol and terbutaline in isolated perfused rat and guinea pig lungs. , 1978, Biochemical pharmacology.

[30]  A. Bye,et al.  Absorption Kinetics after Inhalation of Fluticasone Propionate via the Diskhaler®, Diskus® and Metered-Dose Inhaler in Healthy Volunteers , 2000, Clinical pharmacokinetics.

[31]  T. Fujita,et al.  Lymphatic transfer of macromolecules after intrapulmonary administration in the presence or absence of various absorption enhancers in rats. , 1996, Die Pharmazie.

[32]  Bioequivalence of metered-dose inhaled medications. , 1993, The Journal of allergy and clinical immunology.

[33]  B. Meibohm,et al.  Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration , 1998, European Journal of Clinical Pharmacology.

[34]  J. Patton,et al.  Mechanisms of macromolecule absorption by the lungs , 1996 .

[35]  B. Lipworth,et al.  Pharmacokinetics of chlorofluorocarbon and hydrofluoroalkane metered-dose inhaler formulations of beclomethasone dipropionate. , 1999, British journal of clinical pharmacology.

[36]  P. Thompson.  Drug delivery to the small airways. , 1998, American journal of respiratory and critical care medicine.

[37]  Burkhard Lachmann,et al.  Lung clearance of intratracheally instilled 99mTc‐tobramycin using pulmonary surfactant as vehicle , 1999, British journal of pharmacology.

[38]  I. Gonda.  A semi‐empirical model of aerosol deposition in the human respiratory tract for mouth inhalation , 1981, The Journal of pharmacy and pharmacology.

[39]  S. P. Newman.  Scintigraphic assessment of pulmonary delivery systems , 1998 .

[40]  R. Crystal,et al.  The Lung: Scientific Foundations , 1991 .

[41]  B. Meibohm,et al.  Pharmacokinetic/Pharmacodynamic Evaluation of Systemic Effects of Flunisolide after Inhalation , 1997, Journal of clinical pharmacology.

[42]  D Ganderton,et al.  Assessing lung deposition of inhaled medications. Consensus statement from a workshop of the British Association for Lung Research, held at the Institute of Biology, London, U.K. on 17 April 1998. , 1999, Respiratory medicine.

[43]  P. Valberg,et al.  Breathing patterns influence aerosol deposition sites in excised dog lungs. , 1982, Journal of applied physiology: respiratory, environmental and exercise physiology.

[44]  C. Minto,et al.  Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung. , 2000, British journal of clinical pharmacology.

[45]  F. Morén,et al.  Aerosols in Medicine: Principles, Diagnosis and Therapy , 1993 .

[46]  Forbes,et al.  Human airway epithelial cell lines for in vitro drug transport and metabolism studies. , 2000, Pharmaceutical science & technology today.

[47]  P. Morrow.  LYMPHATIC DRAINAGE OF THE LUNG IN DUST CLEARANCE * , 1972, Annals of the New York Academy of Sciences.